

Plurilock Secures Order with U.S. Pharmaceutical Manufacturer

The order represents the first client in the pharmaceutical industry, providing access to a new market for Plurilock's Technology Division

- Plurilock's advanced continuous authentication software will support the pharmaceutical manufacturer's cybersecurity efforts as the risk of cyberattacks is on the rise
- Healthcare organizations are more susceptible to attacks amidst the COVID-19 pandemic, with U.S. healthcare breaches increasing by 55.1% from 2019 to 2020
- A new report shows one in ten global pharmaceutical manufacturers are at high risk for a ransomware attack

Victoria, British Columbia--(Newsfile Corp. - May 28, 2021) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), an identity-centric cybersecurity solution provider for workforces, has secured an order through GiaSpace, an IT service reseller, to license its advanced continuous authentication software to a regional pharmaceutical manufacturer based in the southeastern United States.

Plurilock was approached to implement its proprietary continuous authentication software to protect against credential sharing, unauthorized access, and phishing attacks to ensure business continuity. In the pharmaceutical industry, an organization's key asset is its intellectual property, and with the continued rise in cyberattacks, a breach could be devastating. The order includes deployment and support for Plurilock's high margin ADAPT and DEFEND products at the manufacturer's facilities.

Recent data shows that healthcare organizations are more susceptible to attacks amidst the COVID-19 pandemic, with U.S. healthcare breaches increasing by 55.1% from 2019 to 2020¹. A new report also shows that one in ten global pharmaceutical manufacturers are at high risk for a ransomware attack².

"Plurilock's high margin software solutions work as a deterrence to attacks and form part of an in-depth defensive cybersecurity strategy, crucial to companies operating today," said Ian L. Paterson, CEO of Plurilock. "Modern-day ransomware is more sophisticated than ever, and these skilled adversaries are finding ways to penetrate networks, identify high-value targets, and access critical information before detonating an attack on systems, causing significant damage and downtime for organizations. With the deployment of Plurilock's authentication software, these organizations will be able to protect the workforce as well as other critical assets against cyberattacks."

The Company's proprietary technology has the ability to recognize individuals and verify identities using cutting edge behavioral biometric signatures, each generated by applying machine learning in the background to personal behavioral and input patterns, physical location, and other contextual data, as device users do their normal work, which will be beneficial for organizations in the pharmaceutical industry.

About Plurilock

Plurilock provides identity-centric cybersecurity for today's workforces. Plurilock offers world-class cybersecurity solutions paired with AI-driven, cloud-friendly security technologies that deliver persistent identity assurance with unmatched ease of use. The Plurilock family of companies enables organizations to operate safely and securely-while reducing cybersecurity friction.

For more information, visit <https://www.plurilock.com> or contact:



Plurilock

To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/85575>